Resources: Single use technologies – the ultimate future
Single use technologies is highly booming in biopharmaceutical sector due to its efficient use and benefits.
List view / Grid view
Single use technologies is highly booming in biopharmaceutical sector due to its efficient use and benefits.
Pharma industry calls for support as restrictive pricing measures and rising costs of goods/inflation could undermine the availability of medicines.
PCI’s Tim Roberts discusses key factors when outsourcing the clinical and commercial supply of biologics, and what makes a strong CDMO partnership.
The importance of thoroughly planned resupply strategies in maintaining clinical supply inventories as studies move into late phase.
The demand for biologics and high potent medicines is forcing the industry to consider alternatives, such as outsourcing and integrated solutions.
Setting a new philanthropic benchmark, Pfizer is launching Accord for a Healthier World - an initiative aimed at closing the gap on inequalities with low-income countries.
Learn strategies to improve supply chain efficiency, reduce risk and respond to local, regional and global challenges.
Learn the benefits of collaboration between the pharmaceutical scientists and clinical supply services teams.
Best practices for leveraging the resources of sourcing vendors are vital to anticipating and avoiding clinical supply delays.
Novartis has suspended production at its radioligand therapy production sites in Ivrea, Italy and Millburn, New Jersey as it addresses potential quality issues identified in its manufacturing processes.
Here, EPR’s Hannah Balfour discusses the latest reports on pharmaceutical counterfeiting and falsification, exploring global and European crime rates, as well as recent counterfeiting incidents reported by Big Pharma.
How to select a CDMO partner for the development and commercial manufacture, packaging and launch of products containing highly potent APIs.
Research suggests companies are often disappointed by new technologies because they have inflated expectations that do not match the tech's practical capabilities.
FUJIFILM Diosynth Biotechnologies will run the cell therapy manufacturing facility, acquired for $100mn from Atara Biotherapeutics, as part of its global network.
Ami Polymer are experts in manufacture of silicone tubing, hose and single use assembly with PPE components, which is demanded in pharma/biopharma industry.